The pills are expected to cost much less then shots of blockbuster drugs like Zepbound and Wegovy. Mr. Funk was the managing ...
In this video, Mikhail Varshavski, DO, who goes by "Dr. Mike," talks with Christle Guevarra, DO, MS, about her struggle with weight, her journey with GLP-1 drugs, and her career in medicine.
Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...
The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.
Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by ...
Novo Nordisk filed an FDA application for weekly CagriSema after trials showed up to 22.7% weight loss versus placebo.
Stocktwits on MSN
Eli Lilly’s oral obesity drug passes maintenance test after Wegovy, Zepbound — Wall Street flags win for Viking Therapeutics
The company studied Orforglipron for weight maintenance over 52 weeks in patients who were on 72 weeks of popular injectable ...
Topline results from the ATTAIN-MAINTAIN trial show that orforglipron, an investigational oral GLP-1 RA, helps people ...
Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...
Seeking Alpha's roundup of statements, announcements, and remarks that could impact markets, sectors, or individual ...
Medicare enrollees will save more than 50% on out-of-pocket costs for 10 common prescription drugs under their insurance ...
According to Lilly, a New Drug Application for orforglipron for the treatment of adults with obesity or overweight has been submitted to the Food and Drug Administration.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback